Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 4
2017 18
2018 12
2019 7
2020 5
2021 5
2022 21
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. Among authors: mccarthy mw. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Free PMC article. Clinical Trial.
Simnotrelvir as a potential treatment for COVID-19.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2024 Feb;25(3):233-237. doi: 10.1080/14656566.2024.2323597. Epub 2024 Feb 27. Expert Opin Pharmacother. 2024. PMID: 38393345 Review.
Progress toward realizing the promise of decentralized clinical trials.
McCarthy MW, Lindsell CJ, Rajasingham R, Stewart TG, Boulware DR, Naggie S. McCarthy MW, et al. J Clin Transl Sci. 2024 Jan 14;8(1):e19. doi: 10.1017/cts.2023.706. eCollection 2024. J Clin Transl Sci. 2024. PMID: 38384913 Free PMC article. No abstract available.
Infliximab Concentrations in Participants with Moderate to Severe COVID-19.
Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW; ACTIV‐1 Study Team. Balevic SJ, et al. Among authors: mccarthy mw. J Clin Pharmacol. 2024 Apr;64(4):490-491. doi: 10.1002/jcph.2388. Epub 2023 Dec 14. J Clin Pharmacol. 2024. PMID: 38031826 No abstract available.
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG, Rebolledo PA, Mourad A, Lindsell CJ, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Bramante CT, Lenert LA, Lim S, Williamson JC, Cardona OQ, Scott J, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Rothman RL, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Stewart TG, et al. Among authors: mccarthy mw. JAMA. 2023 Dec 26;330(24):2354-2363. doi: 10.1001/jama.2023.23363. JAMA. 2023. PMID: 37976072
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
Boulware DR, Lindsell CJ, Stewart TG, Hernandez AF, Collins S, McCarthy MW, Jayaweera D, Gentile N, Castro M, Sulkowski M, McTigue K, Felker GM, Ginde AA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Thicklin F, Wilder R, Wilson S, Shenkman E, Naggie S; ACTIV-6 Study Group and Investigators. Boulware DR, et al. N Engl J Med. 2023 Sep 21;389(12):1085-1095. doi: 10.1056/NEJMoa2209421. N Engl J Med. 2023. PMID: 37733308 Free PMC article. Clinical Trial.
Paxlovid as a potential treatment for long COVID.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1839-1843. doi: 10.1080/14656566.2023.2262387. Epub 2023 Nov 12. Expert Opin Pharmacother. 2023. PMID: 37731377
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O'Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakroysky P, Halabi S, Benjamin DK Jr, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members. O'Halloran JA, et al. Among authors: mccarthy mw. JAMA. 2023 Jul 25;330(4):328-339. doi: 10.1001/jama.2023.11043. JAMA. 2023. PMID: 37428480 Free PMC article.
84 results